To address in vivo anti-tumor effect and safety of EATs, we treated 143B xenografts with 2 × 107 of EATs armed with increasing concentrations (1 to 100 μg) of GD2-BsAb or HER2-BsAb (Fig. 2a). The gene discussed is ERBB2; the disease is neoplasm.